As further proof of the specific targeting of CD56-positive cells in the PBMC population, when we labeled the PBMCs from both the HDs and CLL patients treated ON with scFvB1IL15 and the commercial anti-CD56, we found that the CD56-positive population was almost completely lost. The gene discussed is NCAM1; the disease is B-cell chronic lymphocytic leukemia.